Privosegtor Receives Breakthrough Drug Designation - Top_Thought_Leaders - MDSpire

Privosegtor Receives Breakthrough Drug Designation

In a phase 2 trial, the drug showed functional and structural signals in optic neuritis.

  • By

  • Conexiant News Staff

  • January 6, 2026

  • 2 min

Share

Top Thought Leaders in Ophthalmology

Brief introduction explaining scope and methodology.

Original Source(s)

Privosegtor Receives Breakthrough Drug Designation

  • by Conexiant News Staff

  • January 6, 2026

Related Content

FDA Monthly Preview: Key May Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Redefining Neuro-Ophthalmology

The eye-brain connection and the future of imaging

AAO Updates HCQ Retinopathy Guidance

Updated recommendations emphasize dosing limits and screening for toxicity risk.